Mumbole H*, Coleman RL, Adler AI, Golubic R, Rahman N, Tomlinson J and Caleyachetty R
Chronic Obstructive Pulmonary Disease (COPD) is a significant global health concern, often requiring systemic glucocorticoid treatment during acute exacerbations. However, glucocorticoid use is associated with the development of hyperglycaemia. This study aimed to assess the prevalence of hyperglycaemia in COPD patients treated with systemic glucocorticoids. A comprehensive search of electronic databases was conducted, yielding 18 studies for meta-analysis. The pooled prevalence of hyperglycaemia was 42% (95% CI: 31%-53%), with substantial heterogeneity among studies (I2=97.4%, p<0.001). Subgroup analysis suggested varying prevalence based on study design, publication year, age, BMI, and baseline diabetes status. These findings underscore the importance of monitoring and managing hyperglycaemia in COPD patients receiving glucocorticoid therapy.
Share this article